Locanabio is a biotechnology company that is focused on developing RNA-targeted gene therapies for neurodegenerative diseases. The company was founded in 2017 by Samantha Singer and Gene Yeo, and is based in San Diego, California. Locanabio's technology platform is based on a proprietary RNA-targeting approach that enables the company to selectively modulate gene expression in the brain. The company's lead program is focused on developing a therapy for Huntington's disease, a genetic disorder that causes the progressive breakdown of nerve cells in the brain.